CHMP recommends 8 new medicines for approval in the EU
EU and Korean regulators can now exchange confidential information on medicinal products
How to address vulnerabilities in production and delivery of critical medicines in the EU
International Coalition of Medicines Regulatory Authorities and World Health Organization workshop
How new ACT EU platform will enable collaboration on clinical research
Find medicine
What's new
FAQs
Latest news
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
EMA and the European Commission’s Directorate-General for Health and Food Safety (DG SANTE) have signed a working arrangement with the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for the exchange of confidential information on medical and medicinal products.
EMA’s human medicines committee (CHMP) recommended eight medicines for approval at its April 2024 meeting.
EMA has published a number of recommendations to address vulnerabilities in the production and delivery of medicines included in the Union list of critical medicines and strengthen their supply chain.
Report on COVID-19 vaccine strain updates: global regulators agree on timing and data requirements
GLP-1 receptor agonists: available evidence not supporting link with suicidal and self-injurious thoughts and actions
Information for you
Patients and carers
Healthcare professionals
Animal health professionals
Pharmaceutical Industry
Media
